Headlands Technologies LLC Has $3.23 Million Position in Vaxcyte, Inc. (NASDAQ:PCVX)

Headlands Technologies LLC boosted its holdings in Vaxcyte, Inc. (NASDAQ:PCVX - Free Report) by 41.9% during the 4th quarter, according to the company in its most recent disclosure with the SEC. The fund owned 39,417 shares of the company's stock after buying an additional 11,635 shares during the quarter. Headlands Technologies LLC's holdings in Vaxcyte were worth $3,227,000 as of its most recent SEC filing.

Several other institutional investors and hedge funds have also recently bought and sold shares of the stock. Geode Capital Management LLC raised its position in Vaxcyte by 3.8% during the fourth quarter. Geode Capital Management LLC now owns 2,802,888 shares of the company's stock valued at $229,495,000 after buying an additional 102,106 shares during the period. National Bank of Canada FI acquired a new position in shares of Vaxcyte in the 4th quarter valued at about $41,000. Franklin Resources Inc. lifted its position in shares of Vaxcyte by 3.0% in the fourth quarter. Franklin Resources Inc. now owns 2,869,332 shares of the company's stock worth $234,884,000 after purchasing an additional 82,997 shares in the last quarter. Alliancebernstein L.P. boosted its holdings in shares of Vaxcyte by 8.1% during the fourth quarter. Alliancebernstein L.P. now owns 1,779,362 shares of the company's stock worth $145,659,000 after purchasing an additional 133,448 shares during the period. Finally, Schroder Investment Management Group increased its stake in Vaxcyte by 211.8% in the 4th quarter. Schroder Investment Management Group now owns 44,818 shares of the company's stock valued at $3,675,000 after buying an additional 30,444 shares during the period. Institutional investors and hedge funds own 96.78% of the company's stock.

Remove Ads

Vaxcyte Stock Performance

Shares of Vaxcyte stock traded up $1.04 on Friday, reaching $31.60. The stock had a trading volume of 5,690,652 shares, compared to its average volume of 1,119,961. Vaxcyte, Inc. has a fifty-two week low of $29.57 and a fifty-two week high of $121.06. The business's 50-day moving average price is $74.59 and its two-hundred day moving average price is $89.66. The stock has a market cap of $4.07 billion, a P/E ratio of -6.87 and a beta of 1.26.

Vaxcyte (NASDAQ:PCVX - Get Free Report) last released its earnings results on Tuesday, February 25th. The company reported ($1.02) earnings per share for the quarter, topping analysts' consensus estimates of ($1.16) by $0.14. As a group, equities analysts forecast that Vaxcyte, Inc. will post -4.21 earnings per share for the current fiscal year.

Wall Street Analyst Weigh In

Several research firms have recently commented on PCVX. Evercore ISI upgraded shares of Vaxcyte to a "strong-buy" rating in a report on Monday, March 31st. Guggenheim reaffirmed a "buy" rating and issued a $160.00 target price on shares of Vaxcyte in a research report on Wednesday, March 12th. The Goldman Sachs Group cut their price target on Vaxcyte from $138.00 to $100.00 and set a "buy" rating for the company in a research note on Tuesday. Needham & Company LLC lowered their price target on Vaxcyte from $140.00 to $90.00 and set a "buy" rating for the company in a research note on Tuesday. Finally, Bank of America cut their price objective on shares of Vaxcyte from $157.00 to $137.00 and set a "buy" rating on the stock in a research report on Tuesday. Nine research analysts have rated the stock with a buy rating and one has assigned a strong buy rating to the company's stock. According to MarketBeat.com, Vaxcyte currently has an average rating of "Buy" and an average target price of $136.50.

Insider Activity at Vaxcyte

In related news, Director Teri Loxam sold 6,250 shares of the company's stock in a transaction on Wednesday, January 15th. The shares were sold at an average price of $85.11, for a total transaction of $531,937.50. Following the completion of the transaction, the director now directly owns 7,175 shares in the company, valued at $610,664.25. This represents a 46.55 % decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through this link. Also, CFO Andrew Guggenhime sold 8,000 shares of the stock in a transaction on Tuesday, January 21st. The shares were sold at an average price of $86.51, for a total transaction of $692,080.00. Following the completion of the sale, the chief financial officer now directly owns 109,491 shares of the company's stock, valued at approximately $9,472,066.41. This trade represents a 6.81 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders sold a total of 38,250 shares of company stock worth $3,170,738 in the last 90 days. 3.10% of the stock is owned by company insiders.

Vaxcyte Company Profile

Vaxcyte, Inc, a clinical-stage biotechnology vaccine company, develops novel protein vaccines to prevent or treat bacterial infectious diseases. Its lead vaccine candidate is VAX-24, a 24-valent investigational pneumococcal conjugate vaccine for the prevention of invasive pneumococcal disease. The company also develops VAX-31 to protect against emerging strains and to help address antibiotic resistance; VAX-A1, a novel conjugate vaccine candidate to prevent disease caused by Group A Streptococcus; VAX-PG, a novel protein vaccine candidate targeting keystone pathogen responsible for periodontitis; and VAX-GI to prevent Shigella, a bacterial illness.